Peptides are quickly becoming one of the biggest conversations in health and wellness.
Once discussed primarily inside research labs, medical offices, and niche biohacking communities, peptides are increasingly appearing across telehealth platforms, longevity clinics, podcasts, social media, and personalized wellness programs.
The category is also attracting serious money.
New startups are raising millions of dollars to build peptide-focused healthcare platforms. Established longevity companies are adding physician-guided peptide programs. And major digital health companies are investing in manufacturing infrastructure that could allow them to participate in the market at enormous scale.
The result is what increasingly looks like a new race to build the defining consumer peptide company.
Three companies stand out in 2026: The Protocole, Ways2Well, and Hims & Hers.
While they approach the category very differently, all three demonstrate why peptides could become one of the most closely watched areas of personalized health over the next several years.
Why Peptides Are Suddenly Everywhere
Peptides are short chains of amino acids that play numerous roles throughout the human body.
Importantly, "peptide" describes an enormous category rather than one specific type of treatment.
Some peptide-based drugs are already well established in medicine. Insulin is a peptide hormone, while GLP-1 receptor agonists have transformed diabetes and obesity treatment.
But the current peptide boom stretches far beyond established medications.
Interest has surged around compounds being studied or marketed for areas including recovery, body composition, metabolic health, skin health, cognitive performance, inflammation, sleep, and longevity.
That enthusiasm has created an enormous commercial opportunity — but also significant controversy.
Many peptides promoted online for wellness purposes have not been FDA-approved to treat those conditions, and some lack robust human clinical evidence demonstrating long-term safety and effectiveness.
That distinction matters.
The legitimate business opportunity increasingly appears to be moving away from consumers simply purchasing questionable products online and toward healthcare platforms attempting to combine physician oversight, regulated pharmacy fulfillment, laboratory testing, and personalized protocols.
That is where companies like The Protocole and Ways2Well see an opportunity.
And now much larger companies are paying attention.
1. The Protocole: Building a Peptide-First Health Platform
One of the most interesting newcomers in the space is The Protocole.
Rather than adding peptides as another service inside a traditional wellness clinic, The Protocole is building its identity specifically around them.
The company emerged from stealth in 2026 with $6 million in seed funding led by RARE Capital.
Its goal is to build what it describes as a clinical-grade peptide platform centered around structured protocols, physician oversight, and pharmacy fulfillment.
That positioning is important.
One of the biggest problems surrounding the peptide boom has been fragmented access.
Consumers interested in peptides have historically encountered everything from legitimate medical providers to loosely regulated online sellers and research-chemical websites.
The Protocole is betting that the next generation of consumers will want something more structured.
Instead of simply choosing an individual peptide, the platform organizes its approach around specific health goals and protocols.
That could help turn peptides from a niche biohacking product into something that looks more like personalized healthcare.
The Protocole’s Four Categories
The company organizes its offerings around four primary protocol categories:
Youth — focused on healthy aging and longevity.
Mind — centered around cognitive performance and mental optimization.
Sculpt — designed around body composition and metabolic goals.
Perform — focused on performance, recovery, and physical optimization.
The concept reflects a larger shift occurring throughout wellness.
Consumers increasingly don’t want another supplement bottle or isolated treatment.
They want a system.
Companies like Function Health have helped popularize comprehensive laboratory testing. Oura has made daily recovery and sleep data mainstream. Continuous glucose monitors have introduced consumers to real-time metabolic feedback.
The Protocole is attempting to bring that same structured, personalized approach to peptides.
Why The Protocole Is One to Watch
The company’s biggest advantage may be timing.
Peptide interest is exploding, but there still isn’t an obvious consumer brand that owns the category in the way Oura owns much of the smart-ring conversation or Eight Sleep has become synonymous with temperature-controlled sleep technology.
That leaves room for a company to become the recognizable consumer-facing name in peptides.
The Protocole is attempting to occupy that position early.
Its $6 million seed round also gives the company capital to build infrastructure while the category is still developing.
The biggest challenge will be navigating regulation and ensuring that consumer enthusiasm does not move faster than medical evidence.
If it can do that successfully, The Protocole could become one of the more interesting startups emerging from the longevity movement.
2. Ways2Well: Combining Peptides With the Longevity Movement
The second company worth watching is Ways2Well.
Ways2Well takes a broader approach.
Rather than positioning itself purely as a peptide company, it operates within the growing world of proactive and personalized healthcare.
Its platform combines services including comprehensive bloodwork, supplements, hormone optimization, longevity services, and peptide consultations.
That ecosystem could ultimately be one of its biggest advantages.
Consumers generally aren’t waking up and deciding they need "a peptide."
They are trying to solve a problem.
They want more energy.
Better recovery.
Improved body composition.
Better sleep.
Healthier aging.
Higher athletic performance.
Ways2Well starts with the broader health goal and can then incorporate multiple interventions into a personalized plan.
How Ways2Well Approaches Peptides
Ways2Well offers telehealth peptide consultations with licensed providers.
During the consultation process, providers evaluate an individual’s goals and determine whether a peptide protocol may be appropriate.
The company currently advertises peptide consultations across numerous U.S. states, although availability varies depending on state regulations and individual circumstances.
Ways2Well also integrates peptide access into its broader membership model.
Members can review biomarkers, communicate with providers, receive supplements and prescriptions, and access additional health optimization services.
This makes peptides part of a larger personalized-health ecosystem rather than an isolated product.
The Celebrity and Performance Connection
Ways2Well has also developed significant visibility through the performance and podcast ecosystem.
Its website prominently highlights individuals including Aaron Rodgers, Joe Rogan, Jelly Roll, Sean O’Malley, and Georges St-Pierre.
That association places Ways2Well directly inside the audience currently driving much of the interest in longevity, recovery, hormones, performance medicine, and peptides.
It also demonstrates how differently modern healthcare companies are being built.
The old model of healthcare marketing revolved around hospitals, insurance companies, and traditional advertising.
The emerging wellness model often spreads through podcasts, professional athletes, influencers, founders, and social media.
That distribution engine can be incredibly powerful.
Why Ways2Well Is One to Watch
Ways2Well demonstrates how peptides may eventually fit into the broader longevity economy.
The future may not be consumers purchasing peptides individually.
Instead, peptides could become one component of a larger personalized healthcare membership combining:
Blood testing
Wearable data
Hormone monitoring
Nutrition
Supplements
Recovery technology
Prescription medications
Physician consultations
Peptide therapies
That is essentially the direction Ways2Well is building toward.
And it mirrors a larger shift happening throughout health and wellness: consumers increasingly want one platform capable of understanding their health rather than dozens of disconnected products.
3. Hims & Hers: The Giant Preparing to Take Peptides Mainstream
The third company is different from the first two.
Hims & Hers is already a massive digital healthcare company.
And that is exactly why its entrance into peptides could matter so much.
Hims & Hers has built its business by taking healthcare categories that consumers sometimes find complicated, expensive, or uncomfortable and making them easier to access digitally.
The company initially became known for areas including hair loss and sexual health before expanding into mental health, dermatology, weight management, and other areas of personalized healthcare.
Peptides could represent another major expansion.
Hims Bought a Peptide Manufacturing Facility
In February 2025, Hims & Hers announced that it had acquired a U.S.-based peptide facility in California.
That wasn’t a small strategic experiment.
It represented an investment in the infrastructure necessary to manufacture peptide active pharmaceutical ingredients domestically.
The company said the acquisition could eventually support innovation across areas including:
Preventative health
Metabolic optimization
Cognitive performance
Recovery science
Other personalized health applications
That looks increasingly significant in 2026.
As regulatory discussions around compounded peptides continue, Hims already has something many potential competitors do not: infrastructure.
The company has also expanded internationally through major acquisitions and says it is building toward $6.5 billion in annual revenue and $1.3 billion in adjusted EBITDA by 2030.
That gives Hims a completely different level of scale.
The Potential Peptide Market Is Huge
Analysts cited by Reuters in July 2026 estimated that changes to the regulatory environment could create a peptide market worth approximately $2.2 billion to $3.3 billion.
Hims could be positioned to capture a meaningful portion of that opportunity if regulations ultimately allow expanded access.
The company already has millions of consumers familiar with purchasing healthcare online.
It has clinicians.
It has pharmacy infrastructure.
It has manufacturing capabilities.
It has an enormous digital marketing machine.
And, critically, it has already invested directly in peptide production.
That makes Hims one of the most important companies to watch as the category develops.
Peptides Could Follow the GLP-1 Playbook
The GLP-1 boom offers an interesting preview of what could happen next.
Drugs such as Ozempic, Wegovy, Mounjaro, and Zepbound transformed metabolic health while simultaneously changing consumer expectations around healthcare.
Millions of people became comfortable discussing medications online, using telehealth platforms, tracking metabolic health, and paying for personalized treatments.
Peptides could benefit from that same behavioral shift.
The difference is that the broader peptide category could potentially touch far more areas of wellness.
Recovery.
Longevity.
Body composition.
Metabolic health.
Performance.
Cognition.
Skin.
Sleep.
That creates an enormous potential market — provided the underlying treatments can demonstrate appropriate safety and effectiveness and operate within regulatory requirements.
Why 2026 Could Be a Turning Point for Peptides
The timing of this trend is particularly interesting because the regulatory environment is evolving.
In July 2026, an FDA advisory committee recommended that several peptides, including BPC-157, KPV, TB-500, MOTS-C, Epitalon, and Semax, be eligible for inclusion on a list of bulk drug substances that may be used under certain compounding conditions.
However, an advisory recommendation is not the same as FDA approval of those peptides as drugs, nor does it establish that the compounds are safe or effective for the numerous wellness claims circulating online.
That distinction will be critical as the industry grows.
The winners in this category may ultimately be the companies that can balance consumer demand with strong clinical oversight, transparent sourcing, regulatory compliance, and evidence-based medicine.
The Bigger Trend: Wellness Is Becoming Personalized Medicine
The peptide boom isn’t happening in isolation.
It is part of a much larger transformation.
Consumers are using Oura rings to monitor sleep and recovery.
Companies such as Function Health are making comprehensive blood testing more accessible.
Continuous glucose monitors provide real-time metabolic data.
Eight Sleep is turning the mattress into a health-tracking device.
Longevity clinics are offering full-body imaging, advanced diagnostics, and personalized treatment plans.
As Vital Report has covered in its reporting on the best smart rings of 2026, health tracking is increasingly shifting from occasional doctor visits toward continuous monitoring.
Peptides fit naturally into that movement.
The consumer of the future may not simply visit a doctor once per year.
They may continuously measure their health, identify potential areas for improvement, work with clinicians, and use personalized interventions based on those results.
That is the larger opportunity these peptide companies are pursuing.
The Three Different Bets on Peptides
What’s particularly interesting is that The Protocole, Ways2Well, and Hims & Hers aren’t building the same company.
The Protocole is betting on specialization.
It wants to build a consumer healthcare platform specifically around peptides and structured protocols.
Ways2Well is betting on integration.
It sees peptides as one component of a larger personalized longevity and performance ecosystem.
Hims & Hers is betting on scale.
It already has the healthcare platform, consumer audience, clinicians, pharmacies, marketing capabilities, and increasingly the manufacturing infrastructure needed to potentially bring peptide therapies to a massive audience.
All three strategies could work.
And all three demonstrate just how quickly this category is developing.
What Could Slow the Peptide Boom?
Despite the excitement, peptides remain a complicated category.
Many compounds promoted online have limited human research.
Some are not FDA-approved for the purposes for which they are marketed.
Long-term safety data can be limited or nonexistent.
Quality can also vary significantly depending on how and where a product is produced.
That makes the source of peptide therapies particularly important.
Consumers should distinguish between FDA-approved peptide medications, legitimately prescribed compounded medications when medically appropriate, and "research peptides" sold online without proper medical supervision.
The hype surrounding peptides should never replace clinical evidence.
In fact, this uncertainty may ultimately strengthen the position of companies capable of building trusted, physician-supervised platforms.
The Bottom Line
Peptides are quickly becoming one of the most important emerging categories in personalized health, longevity, and performance.
The Protocole, Ways2Well, and Hims & Hers represent three very different visions for what the industry could become.
The Protocole is building a peptide-first platform backed by fresh venture funding.
Ways2Well is integrating peptides into a broader longevity and personalized-health ecosystem.
Hims & Hers is building the infrastructure that could potentially bring peptide-based care to consumers at massive scale.
But the companies that win won’t simply be the ones that generate the most hype.
They will need to demonstrate that they can combine consumer-friendly healthcare with physician oversight, quality manufacturing, regulatory compliance, and credible science.
If they can, peptides may follow the same path as wearables, GLP-1 medications, continuous glucose monitors, and advanced blood testing — moving from a relatively niche health trend into a significant part of mainstream wellness.
And in 2026, that transition may already be underway.
Frequently Asked Questions
What are the top peptide companies to watch in 2026?
Three companies worth watching are The Protocole, Ways2Well, and Hims & Hers. Each approaches the peptide market differently, ranging from peptide-specific protocols to broader longevity medicine and large-scale telehealth.
What is The Protocole?
The Protocole is a peptide-focused health platform that launched publicly in 2026 after raising a $6 million seed round led by RARE Capital. It focuses on physician-guided protocols organized around health and performance goals.
Does Ways2Well offer peptides?
Ways2Well offers peptide consultations through licensed providers alongside blood testing, supplements, hormone optimization, and other personalized wellness services. Availability varies by location and individual eligibility.
Is Hims & Hers getting into peptides?
Hims & Hers acquired a California-based peptide manufacturing facility in February 2025. The company has said peptide capabilities could eventually support areas including preventative health, metabolic optimization, cognitive performance, and recovery.
Are peptides FDA-approved?
Some peptide-based medications are FDA-approved, but many peptides promoted within the wellness and biohacking industry are not FDA-approved for the uses being advertised. Consumers should distinguish between approved medications, appropriately prescribed compounded medications, and unapproved research products.
Are peptides the next big wellness trend?
Consumer demand, startup investment, telehealth expansion, and regulatory attention suggest peptides could become a significant wellness and personalized-health category. However, the industry’s long-term growth will depend heavily on clinical evidence, regulation, safety, and quality control.